Is metformin beneficial for heart failure in patients with type 2 diabetes?
Abstract
Heart failure is a common and serious cardiovascular complication of type 2 diabetes. Many antihyperglycemic drugs can increase the risk of heart failure. However, it is commonly believed that metformin - the first-line treatment for type 2 diabetes - reduces the risk of and improves the clinical course of heart failure. It is estimated that 20-25% of patients taking metformin have heart failure. Metformin has been shown to have favorable effects on the course of heart failure in experimental models. Furthermore, when compared with other antihyperglycemic medications in nonrandomized epidemiological studies, metformin users had a lower risk of new-onset heart failure and a lower risk of death if they already had heart failure. However, these reports are difficult to interpret, given the potential for prescribing bias and the likelihood that comparator agents caused cardiovascular harm. Meta-analyses of randomized controlled clinical trials have not demonstrated benefits of metformin on the risk of or the clinical course of heart failure. Given metformin's importance in the management of type 2 diabetes and its widespread use in heart failure, the current confidence in its benefits in high-risk patients needs to be re-evaluated.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.